Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Oct;52(4):1262-1272.
doi: 10.4143/crt.2020.089. Epub 2020 May 4.

Increasing Incidence of B-Cell Non-Hodgkin Lymphoma and Occurrence of Second Primary Malignancies in South Korea: 10-Year Follow-up Using the Korean National Health Information Database

Jin Seok Kim  1 , Yanfang Liu  2 , Kyoung Hwa Ha  3 , Hong Qiu  4 , Lee Anne Rothwell  5 , Hyeon Chang Kim  6
Affiliations

Increasing Incidence of B-Cell Non-Hodgkin Lymphoma and Occurrence of Second Primary Malignancies in South Korea: 10-Year Follow-up Using the Korean National Health Information Database

Jin Seok Kim et al. Cancer Res Treat. 2020 Oct.

Abstract

Purpose: The epidemiology of B-cell non-Hodgkin lymphoma (BNHL) in Asia is not well described, and rates of second primary malignancies (SPM) in these patients are not known. We aimed to describe temporal changes in BNHL epidemiology and SPM incidence in Korea.

Materials and methods: A retrospective cohort study used claims data from the National Health Insurance Service that provides universal healthcare coverage in Korea. Newly diagnosed patients aged at least 19 years with a confirmed diagnosis of one of six BNHL subtypes (diffuse large cell B-cell lymphoma [DLBCL], small lymphocytic and chronic lymphocytic [CLL/SLL], follicular lymphoma [FL], mantle cell lymphoma [MCL], marginal zone lymphoma [MZL], and lymphoplasmacytic lymphoma/Waldenström's macroglobulinemia [WM]) during the period 2006-2015 were enrolled and followed up until death, dis-enrolment, or study end, whichever occurred first. Patients with pre-existing primary cancers prior to the diagnosis of BNHL were excluded.

Results: A total of 19,500 patients with newly diagnosed BNHL were identified out of 27,866 with non-Hodgkin lymphoma (NHL). DLBCL was the most frequently diagnosed subtype (41.9%-48.4% of NHL patients annually, 2011-2015). Standardized incidence of the six subtypes studied per 100,000 population increased from 5.74 in 2011 to 6.96 in 2015, with most increases in DLBCL, FL, and MZL. The incidence (95% confidence interval) of SPM per 100 person-years was 2.74 (2.26-3.29) for CLL/SLL, 2.43 (1.57-3.58) for MCL, 2.41 (2.10-2.76) for MZL, 2.23 (2.07-2.40) for DLBCL, 1.97 (1.61-2.38) for FL, and 1.41 (0.69-2.59) for WM.

Conclusion: BNHL has been increasingly diagnosed in Korea. High rates of SPM highlight the need for continued close monitoring to ensure early diagnosis and treatment.

Keywords: Incidence; Korea; Non-Hodgkin lymphoma; Prevalence; Second primary neoplasms.

PubMed Disclaimer

Conflict of interest statement

YL, HQ, and LAR are employees of Janssen Research & Development LLC. YL, HQ, and LAR report stock ownership in Johnson & Johnson Pte Ltd. HCK, KHH, and JSK declare no conflicts of interest. Writing assistance was provided by Joanne Wolter (independent on behalf of Johnson & Johnson Pte Ltd). The work was supported by Janssen Research & Development LLC (Titusville, New Jersey, United States).

Figures

Fig. 1.
Fig. 1.
Age-standardized incidence rates (95% confidence intervals) of B-cell non-Hodgkin lymphoma subtypes in South Korea, 2011-2015. Age-standardized rates were calculated by direct standardization method, using the 2011 Korean population as the reference. p-values for trend: DLBCL p < 0.001 (A), MZL p < 0.001 (B), CLL/SLL p=0.489 (C), MCL p=0.077 (D), FL p < 0.001 (E), WM p=0.661 (F). DLBCL, diffuse large B-cell lymphoma; MZL, marginal zone lymphoma; CLL/SLL, small lymphocytic lymphoma and chronic lymphocytic; MCL, mantle cell lymphoma; FL, follicular lymphoma; WM, Waldenström’s macroglobulinemia or lymphoplasmacytic lymphoma.
Fig. 2.
Fig. 2.
Age-standardized prevalence (95% confidence intervals) of B-cell non-Hodgkin lymphoma subtypes in South Korea, 2011-2015. Age-standardized rates were calculated by direct standardization method, using the 2011 Korean population as the reference. p-values for trend: DLBCL p & 0.001 (A), MZL p & 0.001 (B), CLL/SLL p & 0.001 (C), MCL p & 0.001 (D), FL p & 0.001 (E), WM p & 0.001 (F). DLBCL, diffuse large B-cell lymphoma; MZL, marginal zone lymphoma; CLL/SLL, small lymphocytic lymphoma and chronic lymphocytic; MCL, mantle cell lymphoma; FL, follicular lymphoma; WM, Waldenström’s macroglobulinemia or lymphoplasmacytic lymphoma.
Fig. 3.
Fig. 3.
Age-standardized all-cause mortality rates (95% confidence intervals) in patients with B-cell non-Hodgkin lymphoma subtypes in the Korean population, 2011-2015. Age-standardized rates were calculated by direct standardization method, using the 2011 Korean population as the reference. p-values for trend: DLBCL p < 0.010 (A), MZL p < 0.001 (B), CLL/SLL p < 0.001 (C), MCL p < 0.001 (D), FL p=0.937 (E), WM p=0.923 (F). DLBCL, diffuse large B-cell lymphoma; MZL, marginal zone lymphoma; CLL/SLL, small lymphocytic lymphoma and chronic lymphocytic; MCL, mantle cell lymphoma; FL, follicular lymphoma; WM, Waldenström’s macroglobulinemia or lymphoplasmacytic lymphoma.
Fig. 4.
Fig. 4.
Overall survival after B-cell non-Hodgkin lymphoma diagnosis index date: follow-up of all patients enrolled from 2006-2015 and death from any cause. MZL, marginal zone lymphoma; FL, follicular lymphoma; DLBCL, diffuse large B-cell lymphoma; CLL/SLL, small lymphocytic lymphoma and chronic lymphocytic; MCL, mantle cell lymphoma; WM, Waldenström’s macroglobulinemia or lymphoplasmacytic lymphoma.
Fig. 5.
Fig. 5.
Age-standardized incidence of B-cell non-Hodgkin lymphoma subtypes as reported fan Central Cancer Registry from 1999-2012 [2] and the National Health Information database from 2011-2015 (shaded). DLBCL, diffuse large B-cell lymphoma; CLL/SLL, small lymphocytic lymphoma and chronic lymphocytic; MCL, mantle cell lymphoma; FL, follicular lymphoma; MZL, marginal zone lymphoma.
See this image and copyright information in PMC

References

    1. Armitage JO, Gascoyne RD, Lunning MA, Cavalli F. Non-Hodgkin lymphoma. Lancet. 2017;390:298–310. - PubMed
    1. Lee H, Park HJ, Park EH, Ju HY, Oh CM, Kong HJ, et al. Nationwide statistical analysis of lymphoid malignancies in Korea. Cancer Res Treat. 2018;50:222–38. - PMC - PubMed
    1. Morton LM, Slager SL, Cerhan JR, Wang SS, Vajdic CM, Skibola CF, et al. Etiologic heterogeneity among non-Hodgkin lymphoma subtypes: the InterLymph Non-Hodgkin Lymphoma Subtypes Project. J Natl Cancer Inst Monogr. 2014;2014:130–44. - PMC - PubMed
    1. Feugier P. A review of rituximab, the first anti-CD20 monoclonal antibody used in the treatment of B non-Hodgkin’s lymphomas. Future Oncol. 2015;11:1327–42. - PubMed
    1. Pirani M, Marcheselli R, Marcheselli L, Bari A, Federico M, Sacchi S. Risk for second malignancies in non-Hodgkin’s lymphoma survivors: a meta-analysis. Ann Oncol. 2011;22:1845–58. - PubMed

LinkOut - more resources